FDA Approves the First Generic of Climara Pro, a Once-Weekly Estrogen Plus Progestin Menopause Patch

The U.S. Food and Drug Administration said on October 20, 2026 that it approved the first generic of Climara Pro, the once-weekly estradiol and levonorgestrel patch used to manage menopause symptoms. The applicant is Zydus Pharmaceuticals (USA) Inc., and the agency rates the generic as therapeutically equivalent to the Bayer brand.

Menopausal hormone therapy is one of the treatment categories that women increasingly access through telehealth as well as in person, so a new generic version of an established combination patch is relevant to how clinicians and platforms prescribe it. The approval is a regulatory milestone for the product, not a change to menopause treatment guidelines or to prescribing rules.

What the FDA approved

The approval covers an estradiol and levonorgestrel transdermal system, 0.045 mg per day and 0.015 mg per day, marketed by Zydus Pharmaceuticals (USA) Inc. The FDA describes it as the first generic of Climara Pro, a product first approved in 2003 and held under the Climara Pro trademark by Bayer. A generic rated as therapeutically equivalent carries the same active ingredients, strength, dosage form, and route as the reference drug and can be substituted for it under applicable state pharmacy law.

Climara Pro combines an estrogen (estradiol) with a progestin (levonorgestrel) in a single patch. The progestin is included because unopposed estrogen raises the risk of endometrial cancer in women who still have a uterus, so a combination product is used in that group rather than estrogen alone.

How the patch works and how it is used

According to the Climara Pro labeling, one system is applied once a week to the lower abdomen or the upper quadrant of the buttock, and application sites are rotated with at least a week between uses of the same spot. Each patch delivers a nominal 0.045 mg per day of estradiol and 0.015 mg per day of levonorgestrel. The label notes that a 22 square centimeter system contains 4.4 mg of estradiol and 1.39 mg of levonorgestrel in total.

Delivering the hormones through the skin rather than by mouth is the defining feature of a transdermal product. Whether a transdermal or oral route is appropriate for a given person is a clinical decision, and this approval does not change that.

What it treats

In a woman with a uterus, the product is indicated for treatment of moderate to severe vasomotor symptoms due to menopause, the hot flashes and night sweats many people experience during the menopause transition, and for prevention of postmenopausal osteoporosis. For the osteoporosis use, the labeling advises first considering non-estrogen options and reserving hormone therapy for women at significant risk, consistent with the broader direction to use the lowest effective dose for the shortest duration.

The boxed warning and who should not use it

Because it shares the reference drug's labeling, the generic carries the same boxed warning, titled cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer. The warning draws on the Women's Health Initiative studies, which found increased risks of deep vein thrombosis, pulmonary embolism, stroke, heart attack, and invasive breast cancer among postmenopausal women taking estrogen plus progestin, and an increased risk of probable dementia in women 65 and older. The label states that estrogens should not be used to prevent cardiovascular disease or dementia.

The FDA announcement lists contraindications that mirror the class, including:

• Undiagnosed abnormal genital bleeding
• Breast cancer or a history of it, and other estrogen-dependent cancers
• Active or prior blood clots such as deep vein thrombosis or pulmonary embolism, and active or recent arterial disease such as stroke or heart attack
• Liver impairment or disease, and certain inherited clotting disorders
• Known hypersensitivity to estradiol or levonorgestrel

The most common adverse reactions in the labeling include application site reactions, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, headache, and flu-like symptoms.

Why a first generic matters for cost and access

The FDA runs a program to prioritize and track first generics, the first approved generic versions of brand drugs, because they are typically a point at which competition and lower prices can begin to enter a market. A single approval does not guarantee immediate availability or a specific price, and manufacturers decide when to launch. Over time, additional generic competition tends to reduce out-of-pocket costs for a product.

For patients using hormone therapy for menopause, a therapeutically equivalent generic gives prescribers and pharmacists another option that can be substituted for the brand, subject to state substitution rules and insurance formularies.

What it means for telehealth menopause care

Menopause and hormone therapy are among the fastest growing categories in virtual care, with both general telehealth providers and menopause-focused platforms prescribing estrogen and combination products after a clinical evaluation. A new generic of an established patch expands the set of lower cost products a clinician can choose from, which can matter for people paying cash or facing high formulary tiers.

The approval does not change the rules for how hormone therapy is prescribed, by telehealth or in person. Estrogen plus progestin products are not controlled substances, so they are not subject to the controlled substance telemedicine prescribing rules that affect categories like stimulants and buprenorphine. Prescribing still depends on an appropriate clinical assessment, the boxed warning and contraindications, and each state's rules for establishing a patient relationship.

Limits and what to watch

This is a manufacturing and marketing approval for a generic, not new evidence about the safety or benefit of menopausal hormone therapy, which remains governed by the existing boxed warning and labeling. The FDA announcement did not state a launch date or price, and availability at a given pharmacy or on a given telehealth platform will depend on the manufacturer's rollout and on payer coverage.

This article is general information, not medical advice. Decisions about whether hormone therapy is appropriate, and which product and route to use, should be made with a licensed clinician who can review your personal and family history against the labeling and contraindications.